focus -WSS

focus

author：leisure time 2025-08-11 02:12:42 - browse：589

The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement. It came up most recently in the trials of two police officers accused of causing the death of Elijah McClain, a Colorado man; both officers were acquitted this week.

But excited delirium is not an evidence-based medical diagnosis. The American College of Emergency Physicians recently withdrew a 2009 white paper endorsing the concept, and California has banned it as a cause of death. Other states may follow suit.

On this week’s episode, we are joined by Utsha G. Khatri, an assistant professor of emergency medicine and population health and policy at the Icahn School of Medicine at Mount Sinai, and emergency physician Brooks Walsh, who was involved with the campaign to get ACEP to withdraw the 2009 white paper. Khatri and Walsh speak about why the “excited delirium” label is both unnecessary and dangerous.

“We recognize that some patients are confused. They’re not thinking clearly they might have risk for becoming violent either toward themselves or towards other staff,” Khatri said. “It is our job not just to keep them and everyone else safe, but also to most importantly find out what is causing them to act in this way.”

You can read Khatri’s First Opinion essay on the end of “excited delirium” here.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biden warns of ‘dark winter’ during final presidental debate

WSS

Readout Newsletter: What happened with Sarepta's Duchenne data

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Telehealth options flood the market as retailers push virtual care

The pink breast cancer awareness ribbon needs a redesign

Why patients can’t get everything they want on drug pricing

Emergency medicine has repudiated 'excited delirium.' Now what?

explore

focus

entertainment

Drug repurposing or repositioning? The language matters

What causes rare myocarditis in young men after Covid vaccines?

BioMarin wins approval for gene therapy to treat hemophilia A

Paying for Covid pills will soon shift to insurers

Cancer drug shortages should be causing more outrage

A new crop of companies is reshaping the health data economy

Hollywood unions extend contract negotiations for actors

The battle over 'scope creep' and who gets to be called 'doctor'

DIEP, the 'gold standard' of breast reconstruction, is under threat

The battle over 'scope creep' and who gets to be called 'doctor'

entertainment

A new crop of companies is reshaping the health data economy

Rise in cancer among younger people worries and puzzles doctors

Roche’s Alnylam deal shows drug firms interested in heart drugs

Roche’s Alnylam deal shows drug firms interested in heart drugs

CDC recommends rationing of RSV shot due to shortages

Truvian presents data for its desktop blood

focus

focus

Wikipedia

knowledge